Neogap presents innovative tumour-targeting T-cell therapy at Neoantigen Summit Europe
Neogap Therapeutics, a biotech company specialising in personalised immunotherapy, is pleased to announce that Ola Nilsson, Head of Neoantigen Production and Development, will present the company’s innovative cell therapy pTTL at the 6th Annual Neoantigen Summit Europe in Amsterdam on the 24th - 26th of April. The summit is dedicated to advancing personalised therapeutic development through the discovery of exclusive tumour antigens.
During the presentation, Ola Nilsson will showcase Neogap's advanced software PIOR® for neoantigen prediction and selection and the innovative EpiTCer® technology for efficient antigen delivery, natural processing, and tumour-specific T-cell activation. These technologies are used in the company's cell therapy pTTL (personalised Tumour Trained Lymphocytes), which targets neoantigens to combat cancer and is made from a patient's T cells taken from nearby lymph nodes.
"We are thrilled to share our breakthrough technology with the world's leading experts in neoantigen discovery and development. This is a great opportunity to showcase Neogap's commitment to advancing personalised immunotherapy," says Ola Nilsson.
With over 150 experts in attendance, the Neoantigen Summit Europe is the ideal forum for discussing the validation of neoantigen targets and reviewing methodologies and technologies to support translating neoantigen-based studies effectively to the clinic.
The Neoantigen Summit Europe
When: 24th - 26th April 2023
Where: Amsterdam, the Netherlands
On the 25th of April, Ola Nilsson, Head of Neoantigen Production and Development, will be speaking about 'Evaluating Personalised Tumour-Trained Lymphocytes (pTTL), a Novel, Neoantigen-Targeting T-Cell Therapy Derived from Tumour-Draining Lymph Nodes'.
For more information, registration, and agenda, please visit the Neoantigen Summit Europe website.
For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94
Email: samuel.svensson@neogap.se
About Neogap Therapeutics
Neogap Therapeutics is a Swedish biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at the Center for Molecular Medicine at the Karolinska Institute in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company's website at neogap.se and follow Neogap at LinkedIn.
Tags:
